Nothing Special   »   [go: up one dir, main page]

WO2005074898A3 - Composition comprising (s) pantoprazole and an antibiotic for treating helicobacter pylori - Google Patents

Composition comprising (s) pantoprazole and an antibiotic for treating helicobacter pylori Download PDF

Info

Publication number
WO2005074898A3
WO2005074898A3 PCT/EP2005/050337 EP2005050337W WO2005074898A3 WO 2005074898 A3 WO2005074898 A3 WO 2005074898A3 EP 2005050337 W EP2005050337 W EP 2005050337W WO 2005074898 A3 WO2005074898 A3 WO 2005074898A3
Authority
WO
WIPO (PCT)
Prior art keywords
pantoprazole
antibiotic
composition
helicobacter pylori
treating helicobacter
Prior art date
Application number
PCT/EP2005/050337
Other languages
French (fr)
Other versions
WO2005074898A2 (en
Inventor
Reinhard Huber
Bernhard Kohl
Wolfgang Kromer
Wolfgang-Alexander Simon
Original Assignee
Altana Pharma Ag
Reinhard Huber
Bernhard Kohl
Wolfgang Kromer
Wolfgang-Alexander Simon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag, Reinhard Huber, Bernhard Kohl, Wolfgang Kromer, Wolfgang-Alexander Simon filed Critical Altana Pharma Ag
Publication of WO2005074898A2 publication Critical patent/WO2005074898A2/en
Publication of WO2005074898A3 publication Critical patent/WO2005074898A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising (s) pantoprazole and a helicobacter inhibiting antimicrobial agent, and their use in treating or preventing gastrointestinal disorders, in particular disorders caused or exacerbated by helicobacter infection and secreted gastric acid.
PCT/EP2005/050337 2004-01-28 2005-01-27 Composition comprising (s) pantoprazole and an antibiotic for treating helicobacter pylori WO2005074898A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04001756 2004-01-28
EP04001756.8 2004-01-28

Publications (2)

Publication Number Publication Date
WO2005074898A2 WO2005074898A2 (en) 2005-08-18
WO2005074898A3 true WO2005074898A3 (en) 2006-07-27

Family

ID=34833547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/050337 WO2005074898A2 (en) 2004-01-28 2005-01-27 Composition comprising (s) pantoprazole and an antibiotic for treating helicobacter pylori

Country Status (1)

Country Link
WO (1) WO2005074898A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI463998B (en) * 2009-12-31 2014-12-11 Synmosa Biopharma Corp Amoxicillin and clomycin have a high absorption rate of pharmaceutical ingredients
CN104814964B (en) * 2015-04-16 2018-07-31 广东赛烽医药科技有限公司 A kind of pharmaceutical composition, the preparation method and applications of anti-stomach Helicobacter pylori

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003135A1 (en) * 1990-08-24 1992-03-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical compositions containing 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders
US5888535A (en) * 1993-04-27 1999-03-30 Sepracor Inc. Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
WO2000010995A1 (en) * 1998-08-18 2000-03-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel salt form of pantoprazole
WO2000074654A1 (en) * 1999-06-07 2000-12-14 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel preparation and administration form comprising an acid-labile active compound
US20030136698A1 (en) * 2000-06-27 2003-07-24 Andreas Klatt Medicinal product package for eradication therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003135A1 (en) * 1990-08-24 1992-03-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical compositions containing 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders
US5888535A (en) * 1993-04-27 1999-03-30 Sepracor Inc. Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
WO2000010995A1 (en) * 1998-08-18 2000-03-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel salt form of pantoprazole
WO2000074654A1 (en) * 1999-06-07 2000-12-14 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel preparation and administration form comprising an acid-labile active compound
US20030136698A1 (en) * 2000-06-27 2003-07-24 Andreas Klatt Medicinal product package for eradication therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KALE-PRADHAN PRAMODINI B ET AL: "Esomeprazole for acid peptic disorders", ANNALS OF PHARMACOTHERAPY, vol. 36, no. 4, April 2002 (2002-04-01), pages 655 - 663, XP009030827, ISSN: 1060-0280 *
TANAKA MAKOTO ET AL: "Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin", CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 69, no. 3, March 2001 (2001-03-01), pages 108 - 113, XP009030871, ISSN: 0009-9236 *

Also Published As

Publication number Publication date
WO2005074898A2 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
WO2005117870A3 (en) Combination of proton pump inhibitor, buffering agent, and prokinetic agent
WO2007084221A9 (en) Methods and apparatus for identifying subject matter in view data
IL250858B (en) A tetracycline compound, a pharmaceutical composition comprising the tetracycline compound, and the tetracycline compound or the pharmaceutical composition for treating a tetracycline responsive state
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007022535A3 (en) Prodrugs of active agents
WO2008006528A3 (en) Pharmaceutical compositions comprising levetiracetam
WO2006084164A3 (en) Gastric retention and controlled release delivery system
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008009379A3 (en) Active ingredient combinations having insecticide and acaricide properties
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2007075794A3 (en) Oral formulations comprising tigecycline
WO2007022956A3 (en) Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
WO2006120563A3 (en) Antibacterial agents
HK1120421A1 (en) Compositions and their preparation methods for inhibiting gastric acid secretion
WO2006119309A3 (en) 19,26,27-TRINOR-1α,25-DIHYDROXYVITAMIN D3 COMPOUNDS
WO2011037411A3 (en) Composition comprising s-allyl-l-cysteine as active ingredient for preventing or treating gastrointestinal disorders
WO2007025988A3 (en) Liquid formulations of pegylated growth hormone
WO2005007115A3 (en) Pharmaceutical composition for inhibiting acid secretion
WO2006091836A8 (en) Formulations of ladostigil tartrate
WO2007134158A3 (en) Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy
WO2007133944A3 (en) Topical administration of acyclovir
WO2007087026A3 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
WO2009059755A3 (en) Novel neurturin conjugates for pharmaceutical use
WO2008105826A3 (en) Compositions compromising lysostaphin variants and methods of using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase